News | May 14, 2022
CCMB develops India’s first mRNA vaccine technology
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Subscribe To Our Newsletter & Stay Updated
